drugset
drugset / Trial / NCT02040207

AM-101 in the Treatment of Post-Acute Tinnitus 2

NCT02040207 ↗

Phase 3 Completed 487 enrolled Auris Medical AG
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to test the safety and local tolerance of repeated treatment with AM-101.

Timeline

Start
2014-06
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified — Other

Indications

tinnitus